Bumble Inc vs 10X Genomics Inc — how do they compare? Bumble Inc trades at $2.62 (market cap $366.87M), while 10X Genomics Inc trades at $57.7 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 20.7× Bumble Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Bumble Inc nearer its low. Which is the better fit depends on your goals.
| BMBL | TXG | |
|---|---|---|
Market Cap | $366.87M | $7.61B |
Sector | Technology | Health |
52-Week High | $7.17 | $58.57 |
52-Week Low | $2.70 | $11.34 |
Enterprise Value | $672.73M | $7.14B |
Signals from Pluang's Aura AI — not financial advice
Bumble (BMBL) trades at $2.59, down 5.13% with bearish technical signals and negative earnings momentum after Q2 2026 missed expectations. The company faces declining revenue and persistent net losses despite a high gross margin of 72.84%. Recent strategic shifts include removing the women-first messaging rule and exploring a potential sale to revive growth amid user engagement challenges.
The outlook remains cautious with significant execution risks from product overhauls and competitive pressures. While valuation ratios like P/S (0.38) and P/B (0.71) appear attractive, profitability concerns and negative cash flow trends offset potential upside. Analyst consensus is mixed with a $3.62 price target but 74% hold ratings reflecting uncertainty.
TXG trades at $57.77, down 1.37% today, with a bullish technical outlook supported by moving averages and strong support at $55. The company shows improving fundamentals with Q2 2026 earnings beating estimates and positive cash flow trends, though it remains unprofitable with negative margins. Recent news highlights collaborations with major medical institutions and strategic acquisitions expanding multiomics capabilities.
Investment outlook is mixed: technical strength and analyst upgrades suggest near-term upside potential, but high valuation multiples and persistent losses pose significant risks. The stock faces pressure from competitive threats and execution challenges in achieving profitability, requiring careful monitoring of upcoming Q3 earnings and revenue growth sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →